财中社8月8日电中国生物科技服务(08037)发布公告,预计截至2025年6月30日的中期期间,公司拥有者应占亏损将不超过3300万港元,较2024年同期的7992万港元减少约59%。此次亏损减少的主要原因是公司成功实施了成本控制措施,导致毛利率上升及行政开支减少。此外,公司还获得了约1400万港元的保险赔偿收入,涉及2024年暴雨对海南建筑工地造成的损害。公告指出,上述数据基于管理层对管理账目的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.